Drug-Induced Cardiotoxicity Market Analysis By Type (Chemotherapy-Induced Cardiotoxicity, Antipsychotic Drug-Induced Cardiotoxicity), By Detection (Biomarkers, Imaging Techniques), By Drug Class (Tyrosine Kinase Inhibitors (TKIs), Antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: June 2024
Report ID: 73803
Number of Pages: 295
Format:

Fact Checked

Cite this Research

- 1.Drug-induced Cardiotoxicity Market Introduction
  - 1.1.Definition
  - 1.2.Taxonomy
  - 1.3.Research Scope
- 2.Executive Summary
  - 2.1.Key Findings by Major Segments
  - 2.2.Top strategies by Major Players
- 3.Global Drug-induced Cardiotoxicity Market Overview
  - 3.1.Drug-induced Cardiotoxicity Market Dynamics
    
    3.1.1.Drivers
    
    3.1.2.Opportunities
    
    3.1.3.Restraints
    
    3.1.4.Challenges
  - 3.2.COVID-19 Impact Analysis
  - 3.3.COVID-19 Impact Analysis in Global Drug-induced Cardiotoxicity Market
  - 3.4.PESTLE Analysis
  - 3.5.Opportunity Map Analysis
  - 3.6.PORTER'S Five Forces Analysis
  - 3.7.Market Competition Scenario Analysis
  - 3.8.Product Life Cycle Analysis
  - 3.9.Opportunity Orbits
  - 3.10.Manufacturer Intensity Map
  - 3.11.Major Companies sales by Value & Volume
- 4.Global Drug-induced Cardiotoxicity Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Indications, 2015-2031
  - 4.1.Global Drug-induced Cardiotoxicity Market Analysis by Indications: Introduction
  - 4.2.Market Size and Forecast by Region
  - 4.3.Left Ventricle Dysfunction
  - 4.4.Anthracyclines
  - 4.5.Trastuzumab
  - 4.6.Lapatinib
  - 4.7.ABL Inhibitors
  - 4.8.Bortezomib
  - 4.9.Rhythm Disturbances
  - 4.10.Ischaemia
  - 4.11.Fluoropyrimidines
  - 4.12.Taxanes
  - 4.13.Bevacizumab
  - 4.14.Sorafenib
- 5.Global Drug-induced Cardiotoxicity Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by End-Users, 2015-2031
  - 5.1.Global Drug-induced Cardiotoxicity Market Analysis by End-Users: Introduction
  - 5.2.Market Size and Forecast by Region
  - 5.3.Hospitals
  - 5.4.Clinics
  - 5.5.Ambulatory Surgical Centers (ASCs)
- 6.Global Drug-induced Cardiotoxicity Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Region, 2015-2031
  - 6.1.North America
    
    6.1.1.North America Drug-induced Cardiotoxicity Market: Regional Trend Analysis
    
    6.1.1.1.U.S.
    
    6.1.1.2.Canada
    
    6.1.1.3.Mexico
  - 6.2.1.Europe
    
    6.2.1.Europe Drug-induced Cardiotoxicity Market: Regional Trend Analysis
    
    6.2.1.1.U.K.
    
    6.2.1.2.Germany
    
    6.2.1.3.France
    
    6.2.1.4.Spain
    
    6.2.1.5.Italy
    
    6.2.1.6.Russia
    
    6.2.1.7.Rest of Europe
  - 6.3.Asia-Pacific
    
    6.3.1.Asia-Pacific Drug-induced Cardiotoxicity Market: Regional Trend Analysis
    
    6.3.1.1.China
    
    6.3.1.2.Japan
    
    6.3.1.3.South Korea
    
    6.3.1.4.India
    
    6.3.1.5.ASEAN
    
    6.3.1.6.Rest of Asia-Pacific
  - 6.4.Latin America
    
    6.4.1.Latin America Drug-induced Cardiotoxicity Market: Regional Trend Analysis
    
    6.4.1.1.Brazil
    
    6.4.1.2.Argentina
    
    6.4.1.3.Rest of Latin America
  - 6.5.Middle East and Africa
    
    6.5.1.Middle East and Africa Drug-induced Cardiotoxicity Market: Regional Trend Analysis
    
    6.5.1.1.GCC
    
    6.5.1.2.Israel
    
    6.5.1.3.South Africa
    
    6.5.1.4.Rest of MEA
- 7.Global Drug-induced Cardiotoxicity Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1.Market Share Analysis
  - 7.2.Company Profiles
  - 7.3.St. Jude Maedical Plc
    
    7.3.1.Company Overview
    
    7.3.2.Financial Highlights
    
    7.3.3.Product Portfolio
    
    7.3.4.SWOT Analysis
    
    7.3.5.Key Strategies and Developments
  - 7.4.Terumo Cardiovascular Systems Corporation
    
    7.4.1.Company Overview
    
    7.4.2.Financial Highlights
    
    7.4.3.Product Portfolio
    
    7.4.4.SWOT Analysis
    
    7.4.5.Key Strategies and Developments
  - 7.5.Biotronik
    
    7.5.1.Company Overview
    
    7.5.2.Financial Highlights
    
    7.5.3.Product Portfolio
    
    7.5.4.SWOT Analysis
    
    7.5.5.Key Strategies and Developments
  - 7.6.Medtronic Plc
    
    7.6.1.Company Overview
    
    7.6.2.Financial Highlights
    
    7.6.3.Product Portfolio
    
    7.6.4.SWOT Analysis
    
    7.6.5.Key Strategies and Developments
  - 7.7.Boston Scientific Corporation
    
    7.7.1.Company Overview
    
    7.7.2.Financial Highlights
    
    7.7.3.Product Portfolio
    
    7.7.4.SWOT Analysis
    
    7.7.5.Key Strategies and Developments
  - 7.8.Johnson & Johnson
    
    7.8.1.Company Overview
    
    7.8.2.Financial Highlights
    
    7.8.3.Product Portfolio
    
    7.8.4.SWOT Analysis
    
    7.8.5.Key Strategies and Developments
- 8.Assumptions and Acronyms
- 9.Research Methodology
- 10.Contact
- Novartis AG
- Pfizer Inc
- Siemens Healthineers
- GE Healthcare
- Amgen Inc
- Bristol Myers Squibb
- Mayo Clinic
- Cleveland Clinic